menu search

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus […] The post IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update appeared first on ForexTV... Read More
Posted: May 12 2023, 13:05
Author Name: forextv
Views: 102669

Search within

Pages Search Results: